Neil Abdollahian is Chief Business Officer at Cidara Therapeutics, Inc. (CDTX). They have made 5 open-market trades across 1 company since 2019, most recently 2021-04-01.
CIK 0001678223
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CDTX | 55,440 | $12.3M |
Shares reported on the most recent Form 4, priced at the 2021-04-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CDTX | SELL | 2021-01-05 | 2021-04-05 | $2.26 | $10K | -15.2% | -21.4% | -25.7% |
| CDTX | SELL | 2020-01-03 | 2020-01-06 | $3.42 | $8K | +0.8% | -19.5% | -33.0% |
| CDTX | SELL | 2020-01-03 | 2020-06-25 | $3.42 | $3K | -4.8% | -1.0% | -25.5% |
| CDTX | SELL | 2019-10-01 | 2019-10-03 | $1.98 | $14K | -0.5% | +24.2% | +79.5% |
| CDTX | SELL | 2019-03-08 | 2019-03-08 | $2.44 | $6K | +4.5% | +18.4% | -31.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.